KURA ONCOLOGY ($KURA) posted quarterly earnings results for Q4 2025 on Thursday, March 5th. The company reported earnings of -$0.92 per share, missing estimates of -$0.62 by $0.30. The company also reported revenue of $17,340,000, missing estimates of $54,624,927 by $-37,284,927.
You can see Quiver Quantitative's $KURA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
KURA ONCOLOGY Insider Trading Activity
KURA ONCOLOGY insiders have traded $KURA stock on the open market 30 times in the past 6 months. Of those trades, 1 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $KURA stock by insiders over the last 6 months:
- TROY EDWARD WILSON (President and CEO) has made 1 purchase buying 50,000 shares for an estimated $410,145 and 1 sale selling 36,615 shares for an estimated $327,418.
- MOLLIE LEONI (Chief Medical Officer) has made 0 purchases and 6 sales selling 35,979 shares for an estimated $352,397.
- TERESA BROPHY BAIR (Chief Legal Officer) has made 0 purchases and 5 sales selling 28,817 shares for an estimated $271,965.
- FRANCIS BURROWS (Chief Scientific Officer) has made 0 purchases and 2 sales selling 25,037 shares for an estimated $243,023.
- BRIAN T. POWL (Chief Commercial Officer) has made 0 purchases and 4 sales selling 24,192 shares for an estimated $233,100.
- KATHLEEN FORD (Chief Operating Officer) has made 0 purchases and 3 sales selling 15,607 shares for an estimated $154,111.
- THOMAS JAMES DOYLE (SVP, Finance & Accounting) has made 0 purchases and 7 sales selling 16,222 shares for an estimated $151,764.
- FAHEEM HASNAIN sold 10,000 shares for an estimated $109,764
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
KURA ONCOLOGY Hedge Fund Activity
We have seen 132 institutional investors add shares of KURA ONCOLOGY stock to their portfolio, and 100 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STATE STREET CORP added 1,587,959 shares (+47.5%) to their portfolio in Q4 2025, for an estimated $16,498,894
- ALGERT GLOBAL LLC removed 1,011,945 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $10,514,108
- RENAISSANCE TECHNOLOGIES LLC added 965,256 shares (+111.6%) to their portfolio in Q4 2025, for an estimated $10,029,009
- ECOR1 CAPITAL, LLC removed 872,500 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $9,065,275
- AQR CAPITAL MANAGEMENT LLC added 820,020 shares (+36.6%) to their portfolio in Q4 2025, for an estimated $8,520,007
- FORESITE CAPITAL MANAGEMENT IV, LLC removed 816,882 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $7,229,405
- GOLDMAN SACHS GROUP INC removed 777,462 shares (-29.7%) from their portfolio in Q4 2025, for an estimated $8,077,830
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
KURA ONCOLOGY Analyst Ratings
Wall Street analysts have issued reports on $KURA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/24/2025
- UBS issued a "Buy" rating on 11/14/2025
- Wedbush issued a "Outperform" rating on 11/14/2025
- JMP Securities issued a "Market Outperform" rating on 10/20/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/30/2025
To track analyst ratings and price targets for KURA ONCOLOGY, check out Quiver Quantitative's $KURA forecast page.
KURA ONCOLOGY Price Targets
Multiple analysts have issued price targets for $KURA recently. We have seen 6 analysts offer price targets for $KURA in the last 6 months, with a median target of $26.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $40.0 on 01/13/2026
- An analyst from Leerink Partners set a target price of $20.0 on 01/13/2026
- Etzer Darout from Barclays set a target price of $28.0 on 11/24/2025
- Robert Driscoll from Wedbush set a target price of $38.0 on 11/14/2025
- David Dai from UBS set a target price of $16.0 on 11/14/2025
- Reni J. Benjamin from JMP Securities set a target price of $24.0 on 10/20/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
